New Study Suggests Ashwagandha Extract May Boost Memory in Mild Cognitive Impairment

A recent clinical trial published in the Journal of Psychopharmacology indicates that an ashwagandha extract, standardized with a compound called Sominone, might enhance memory and cognitive performance in individuals with mild cognitive impairment (MCI). Participants who consumed the supplement daily for two months exhibited notable improvements in various memory and spatial reasoning tasks compared to those on a placebo. The supplement appeared to be well-tolerated, with no major side effects reported.

Mild cognitive impairment, or MCI, describes a noticeable decline in memory or cognitive abilities that does not significantly disrupt daily life. Individuals with MCI are at increased risk of developing dementia later, including Alzheimer’s disease.

At present, there are no formally approved medications specifically targeting MCI. Many people resort to lifestyle changes such as exercise, diet adjustments, and cognitive training to slow cognitive decline. Herbal supplements have attracted interest, with ashwagandha, a plant used in traditional Indian medicine, frequently recommended for stress, anxiety, and cognitive enhancement.

Ashwagandha, scientifically known as Withania somnifera, has been utilized in Ayurveda, India’s traditional medical system. Recent findings suggest its compounds may provide neuroprotective benefits. Specifically, Sominone, a metabolite from one of the plant’s active ingredients, has shown promise in animal studies, supporting nerve cell growth and protecting neurons from harm while enhancing memory performance. This study aimed to examine whether the standardized extract containing Sominone (referred to as Somin-On™) could yield similar benefits in humans with MCI.

The researchers conducted a randomized, double-blind, placebo-controlled pilot study at a medical center in Jhansi, India. Forty adults with MCI, aged between 25 and 65 and demonstrating mild memory issues via standard clinical assessments, participated. They were randomly assigned to receive either 250 mg of Somin-On™ or a placebo capsule daily for 60 days. Neither participants nor researchers were aware of who received the treatment versus the placebo.

Cognitive function was evaluated using various standardized assessments, including the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Wechsler Memory Scale-III (WMS-III), and Shepard Mental Rotation Task. These tests were administered at the beginning, the midpoint, and the end of the study. Researchers focused on changes in immediate memory, general memory, working memory, attention, and visuospatial processing.

The results were quite compelling. Participants taking Somin-On™ showed consistent and statistically significant improvements across nearly all assessed areas compared to those receiving a placebo. Changes were observable after just 30 days of treatment, with greater enhancements noted by the end of the 60-day period.

For instance, performance on the Shepard Mental Rotation Task, measuring spatial reasoning and mental imagery, improved by 12% at 30 days and 32% at 60 days for the Somin-On™ group, while the placebo group experienced a decline over the same timeframe. Similar patterns were noted in the Wechsler Memory Scale results.

In terms of immediate memory, participants on the supplement improved roughly 7% at 60 days, whereas those on the placebo slightly declined. General memory scores saw nearly a 15% rise in the treatment group, contrasting with a minor increase in the placebo group. Working memory also showed an improvement exceeding 18% in those taking Somin-On™, with negligible changes in the control group.

Remarkable improvements were observed in both MoCA and MMSE scores. In the treatment group, MoCA scores increased nearly 15% from the baseline, while MMSE scores went up by over 19%, both significantly outperforming the placebo group.

No adverse effects were reported by participants in either group, and routine blood tests along with liver and kidney markers remained stable during the trial.

The researchers propose that the cognitive enhancements linked to Somin-On™ may arise from its neuroprotective properties. Previous research in animals has indicated that Sominone can foster neural connections and reverse memory loss caused by brain cell damage. It has also been associated with improved spatial memory and reduced brain cell shrinkage in models of Alzheimer’s disease, pointing toward a potential mechanism that supports the development and maintenance of neural networks rather than merely addressing typical neurodegeneration indicators.

Other possible mechanisms could include increased resistance to oxidative stress, better mitochondrial function, and enhanced cholinergic signaling—factors all connected to memory functions. Inflammation and excitotoxicity, common processes in neurodegeneration, may also be mitigated by components found in ashwagandha. Even though this study didn’t directly analyze these mechanisms, the cognitive improvements observed might relate to one or several of these biological pathways.

Nonetheless, the study has its limitations. The small sample size of 40 participants means that additional research is necessary to confirm these findings and understand their broader implications. Additionally, the study lasted just two months, leaving uncertain whether the benefits of Somin-On™ could extend beyond this period or potentially prevent further cognitive decline. Moreover, the lack of imaging techniques or biological markers to explore brain changes leaves the underlying mechanisms behind the cognitive enhancements somewhat unclear.

Another limitation is the absence of an active comparator group. While the study contrasted Somin-On™ with a placebo, it didn’t juxtapose it against other forms of ashwagandha or other cognitive-enhancing treatments. Given that ashwagandha contains various bioactive compounds, future investigations might want to discern if Sominone is solely responsible for the benefits or if they stem from a broader array of constituents.

The researchers encourage future trials to incorporate a more varied participant demographic, prolonged follow-up periods, and potentially include imaging or biomarker data to examine the impact of ashwagandha on brain structure and function. Testing the supplement alongside other non-pharmaceutical interventions, like cognitive training or exercise, could also be beneficial.